Paraplatin (carboplatin)

May 25, 2018May 25, 2018

Mirvetuximab Soravtansine Combo Therapies Show Promise for Ovarian Cancer, Clinical Trial Shows

News

Combinations of mirvetuximab soravtansine (IMGN853) with either Avastin (bevacizumab) or Paraplatin (carboplatin) are showing promise in certain ovarian cancer patients, particularly those who received multiple prior lines of therapy, the investigational therapy’s developer, ImmunoGen, recently announced. ... Read more

March 2, 2018March 2, 2018

Scientists Discover Gene Variant that Could Help Predict Chemo Outcomes

News

Researchers have discovered new gene variants that affect how ovarian cancer patients respond to standard chemotherapy treatments Paraplatin (carboplatin) and Taxol (paclitaxel). The variants influence how a patient processes chemotherapy medications. ... Read more

September 27, 2017September 27, 2017

Chemotherapy Every 3 Weeks Seen as Effective as Weekly Dosing in European Ovarian Cancer Patients

News

Researchers compared weekly doses of Taxol (paclitaxel) to treat ovarian cancer with dosing every three weeks in a European trial to determine if weekly dosing was more effective. They found that ... Read more